Vanguard Personalized Indexing Management LLC Boosts Position in Exact Sciences Corporation $EXAS

Vanguard Personalized Indexing Management LLC lifted its stake in shares of Exact Sciences Corporation (NASDAQ:EXAS) by 22.0% during the 2nd quarter, Holdings Channel reports. The fund owned 15,796 shares of the medical research company’s stock after buying an additional 2,853 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Exact Sciences were worth $839,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of EXAS. Larson Financial Group LLC raised its holdings in shares of Exact Sciences by 2,804.8% during the 1st quarter. Larson Financial Group LLC now owns 610 shares of the medical research company’s stock worth $26,000 after acquiring an additional 589 shares during the period. National Pension Service increased its position in shares of Exact Sciences by 75.1% during the 1st quarter. National Pension Service now owns 681 shares of the medical research company’s stock worth $29,000 after purchasing an additional 292 shares during the last quarter. SVB Wealth LLC acquired a new stake in shares of Exact Sciences during the 1st quarter worth about $30,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Exact Sciences during the 1st quarter worth about $34,000. Finally, Banque Cantonale Vaudoise acquired a new stake in shares of Exact Sciences during the 1st quarter worth about $34,000. Hedge funds and other institutional investors own 88.82% of the company’s stock.

Insiders Place Their Bets

In other Exact Sciences news, Director James Edward Doyle sold 2,000 shares of Exact Sciences stock in a transaction dated Thursday, October 9th. The stock was sold at an average price of $60.00, for a total value of $120,000.00. Following the completion of the transaction, the director directly owned 57,962 shares of the company’s stock, valued at $3,477,720. The trade was a 3.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.20% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

EXAS has been the subject of a number of recent analyst reports. Cowen reissued a “buy” rating on shares of Exact Sciences in a research report on Thursday, August 7th. Evercore ISI raised their price objective on Exact Sciences from $64.00 to $68.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. Wall Street Zen raised Exact Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Exact Sciences in a research report on Wednesday, October 8th. Finally, Wells Fargo & Company set a $68.00 price objective on Exact Sciences in a research report on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $69.19.

Exact Sciences Stock Performance

NASDAQ EXAS opened at $61.23 on Monday. The company has a market cap of $11.59 billion, a P/E ratio of -11.28, a P/E/G ratio of 5.43 and a beta of 1.24. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.89 and a quick ratio of 2.56. The stock has a 50-day moving average of $52.24 and a two-hundred day moving average of $51.16. Exact Sciences Corporation has a 1-year low of $38.81 and a 1-year high of $72.83.

Exact Sciences (NASDAQ:EXAS) last released its earnings results on Wednesday, August 6th. The medical research company reported $0.22 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.24. The company had revenue of $811.09 million during the quarter, compared to the consensus estimate of $774.43 million. Exact Sciences had a negative return on equity of 1.75% and a negative net margin of 34.19%.Exact Sciences’s revenue was up 16.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.09) EPS. As a group, analysts anticipate that Exact Sciences Corporation will post -0.58 EPS for the current year.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.